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ABSTRACT 
Objective: The proposed research work was conducted to develop a single reverse-phase high-performance chromatography (RP-HPLC) method 
capable of separating two Pharmacopoeial related impurities as well as degradation product of Tolfenamic acid (TA). The drug was subjected to 
various stress conditions recommended under ICH Q1A (R2) guidelines. 
Methods: The desired separation of two Pharmacopoeial impurities and one degradant generated under oxidative stress was carried out using 
Sunfire ODS C-18 (250 x 4.6 mm, 5 µm) column maintained at 40 °C. Isocratic elution was carried out using acetonitrile and ammonium dihydrogen 
orthophosphate buffer (10 mmol, pH 2.5) in the ratio of 80:20 v/v. The detection was carried out at 205 nm using flow rate of 1 ml/min. The 
developed method was validated as per ICH Q2 (R1) guidelines for specificity, linearity, accuracy, precision, Limit of detection (LOD), Limit of 
Quantification (LOQ) and robustness. 
Results: Linearity response of TA was found at a concentration range of 10-100µg/ml, with a correlation coefficient of 0.9987. The Pharmacopoeial 
impurity A and impurity B showed linearity results at concentration of 0.1-1µg/ml, with correlation coefficient of 0.9984 for Impurity A and 0.9989 
for Impurity B. The % recovery during accuracy studies for TA and the two impurities were within the acceptance range of 95-105%. LOD and LOQ 
for TA were found to be 4.561µg/ml and 133.771µg/ml respectively. For impurity A, LOD and LOQ were found to be 0.035 µg/ml and 0.106 µg/ml 
and for Impurity B, LOD and LOQ were 0.042 µg/ml and 0.128 µg/ml. With slight variation of organic phase in mobile phase and flow rate the 
method exhibited good robustness. Under forced degradation studies the drug was found stable under hydrolytic, photolytic and thermal stress 
conditions, but was found susceptible for degradation under oxidative stress with appearance of a degradant peak. From on the RRT values of 
Pharmacopoeial impurities and the formed degradant it was inferred that the developed method is selective for the drug in the presence of 
impurities or degradants.  
Conclusion: The developed stability-indicating method is found to be simple, rapid, accurate, precise and robust as compared to other proposed 
methods while determining TA in presence of its Pharmacopoeial impurities and degradation products. Hence the developed method can be used 
for analysis of stability samples of TA in presence of its related impurities. 
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Tolfenamic acid (TA) is 2-[(3-chloro-2-methylphenyl) amino] benzoic 
acid (fig. 1) [1]. British pharmacopoeia lists three impurities in the 
monograph of TA (fig. 1) [2]. TA belongs to the class of fenamates of 
the nonsteroidal anti-inflammatory drug (NSAID) and is used for 
treatment of inflammation and pain in humans as well as animals. 
Mostly used for the remedy of acute migraine attacks and for the relief 
of pain in conditions such as osteoarthritis, dysmenorrhea and 
rheumatoid arthritis [3-4]. TA has gained high popularity recently for 
its anticancer activity against different types of cancer [5-8]. The 
concentration of all the related substances associated with drug as per 
ICH guidelines must be less than 0.2% of the concentration of drug 
except for isopropyl ethers and monoester, whereas the limit should 
not exceed 0.2% at different storage concentrations [9].  
Study on TA by various analytical methods has been reported in the 
literature. Few of them include titrimetry [10], spectrophotometry 
[11], spectrofluorimetry [12] and reversed phase high-performance 
liquid chromatography (RP-HPLC) methods [13–20]. A literature 
highlighted the separation of two related impurities of TA i.e. 2-
chlorobenzoic acid (CBA) and 3-chloro-2-methylaniline (CMA) by 
HPLC and TLC densitometric method [21] without commenting on 
the stability-indicating potential of the method. Whereas minimum 
literature, till date is an available wherein stability-indicating 
method for TA by RP HPLC in presence of its related impurities, has 
been reported.  
Hence the current work was undertaken to develop and validate a 
RP–HPLC method for the estimation of TA in the presence of its two 
Pharmacopoeial impurities i.e. Impurity A (CBA) and Impurity B 
(CMA) and also perform as a stability-indicating method. The drug 
was subjected to various stress conditions of hydrolysis, oxidation, 
photolysis and thermal as per ICH guidelines [22]. The developed 
method is the first report of its kind which could be applied for 
effective separation of TA from its Pharmacopoeial impurities and 
other degradants formed under stress conditions.  
 
 
Fig. 1: A) Chemical structure of Tolfenamic acid, B) Chemical 
structure of 2-chlorobenzoic acid (Impurity A), C) Chemical 
structure of 3-chloro-2-methyl aniline (Impurity B) and D) 
Chemical structure of 3-chloro-4-methyl-9-oxo-9, 10-
dihydropyridine (Impurity C) 
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MATERIALS AND METHODS 
Chemicals 
Tolfenamic acid was obtained as a gift sample from Pure and Cure 
Healthcare Ltd (Uttarakhand, India). Impurities were purchased from 
Sigma-Aldrich Co., St. Louis, MO, USA. The Chemicals used in this work 
include, Acetonitrile (HPLC grade–Rankem, India),whereas 
ammonium dihydrogen orthophosphate (AR), orthophosphoric acid 
(AR), ammonia solution (AR), Hydrochloric acid(HCl)(AR), Sodium 
hydroxide(NaOH) (AR), and hydrogen peroxide (10%, v/v) (AR), were 
procured from Merck, India. HPLC grade water used in the study was 
obtained from Bio-age water purification system. All the solvents and 
sample solutions were filtered through 0.45 μm membrane filter 
before injecting into the HPLC system.  
HPLC Instrument and chromatographic conditions 
In the current research work, Jasco LC-4000 series HPLC system 
consisting of a quaternary solvent delivery system, an on-line 
degasser, an auto-sampler, a column temperature controller and a 
diode array detector was used. System control and data analysis were 
processed with Jasco Chrom NAV software. Other instruments utilized 
in the study include Bath sonicator (Citizon Ultrasonic cleaner); Digital 
Balance (Wensar Digital Electronic Balance) and pH meter 
(Labtronics, LT-10). Optimum separation and estimation were 
achieved on Sunfire ODS C18 column (250×4.6 mm, 5 μm) from 
Waters. The mobile phase used for the study involved acetonitrile and 
10 mmol ammonium dihydrogen ortho phosphate buffer (pH adjusted 
to 2.5 with o-phosphoric acid) in the ratio of 80:20 v/v, with flow rate 
of 1 ml/min. Studies were performed with column temperature at 40 
°C, and injecting volume as 10μl with detection wavelength of 205 nm. 
Buffer solution 
10 mmol ammonium dihydrogen ortho phosphate buffer was 
prepared by dissolving 1.15 g of ammonium dihydrogen ortho 
phosphate in HPLC water and the volume was made up to the mark 
in a standard 1 litre volumetric flask. The pH was adjusted to 2.5 
using ortho phosphoric acid solution. The prepared buffer solution 
was filtered through 0.45 µ membrane filter. 
Stock standard solutions (1,000 µg/ml) 
Stock standard solutions of TA, CBA, and CMA were prepared by 
weighing separately and accurately 10 mg of pure powder of each 
into three separate 10 ml standard volumetric flasks. Sufficient 
quantity of acetonitrile was added in all the volumetric flasks and 
sonicated for 15 min to dissolve the substance. The final volumes 
were made to the mark with acetonitrile and mixed well.  
Working standard solutions (100 µg/ml) 
Working standard solutions of CBA and CMA were prepared by 
accurately transferring 1 ml each of CBA and CMA from their 
respective stock standard solutions (1,000 µg/ml) into 2 separate 10 
ml volumetric flasks. Volume up to the mark was made with 
acetonitrile to get 100 µg/ml working standard of each component. 
Selection of the detection wavelength for the method  
Spectra scan of the three components in the range of 190 nm to 400 
nm was run. From the Overlays of the spectra’s the wavelength that 
showed sufficient absorbance of all the components was selected for 
the study. Thus Wavelength of 205 nm was selected as the detection 
wavelength for the current method.  
Method validation 
The developed RP HPLC method for separation of specified 
impurities and possible degradants obtained of TA was validated as 
per ICH guidelines Q2 (R1) [23]. 
Specificity 
The specificity of the method was evaluated by application of the 
developed method to a mixture containing 10µg/ml concentration of 
TA, and 1µg/ml of CBA and CMA. Specificity of the method was also 
checked for the samples of TA subjected to various forced/stressed 
conditions as per ICH guideline. Specificity of the method was 
confirmed by calculating system suitability testing parameters such 
as resolution, peak asymmetry, and no of theoretical plates, for the 
separated chromatographic peaks and the formed degradants peaks.  
Linearity and range 
Fixed volumes equivalent to 10–100 µg/ml of TA were separately 
transferred from the stock standard solution of TA (1,000 µg/ml) into 10 
ml volumetric flask and the volume was made up to the mark with the 
mobile phase. For impurities, volumes equivalent to 0.1-1 µg/ml of CBA, 
and CMA were separately transferred from their respective working 
standard solutions (100 µg/ml) into 10 ml volumetric flasks. The volume 
was made to the mark with the mobile phase. Six 10 µl injections were 
given of each concentration. The calibration curves were plotted and the 
regression parameters were obtained. 
Precision 
Intraday repeatability and interday repeatability of the method was 
evaluated by analyzing 40 µg/ml concentration of and 0.4 µg/ml 
concentrations of each impurity. Interday precision was done on two 
successive days using the same procedure stated under 
chromatographic conditions. The percentage relative standard 
deviation (%RSD) values were then calculated. 
Accuracy 
Accuracy of the developed method was determined by recovery 
studies using standard addition method. The percentage recovery 
studies of TA, CBA, and CMA was carried out in triplicate at 3 
different levels of 80%, 100%, 120%.  
Sensitivity 
The sensitivity of the developed method was determined by 
calculating LOD and LOQ for TA and its two impurities. LOD and LOQ 
were calculated for TA and its two impurities based on the Standard 
deviation of the Response and the Slope as mentioned below. 
LOD = 3.3 X Standard deviation of the response/Slope of the 
calibration curve 
LOQ = 10 X Standard deviation of the response/Slope of the 
calibration curve 
Robustness  
The robustness of the method was done to check the effect of small 
deliberate changes in the chromatographic conditions. Changes in 
the flow rate of the mobile phase (±0.2 unit) and the proportion of 
organic phase in the mobile phase (±2 units) on the developed 
method were studied. The system suitability parameters where 
checked for verifying the robustness of the method. 
Forced degradation studies 
To assess the stability-indicating power and specificity of the 
method, forced degradation studies were performed. Forced 
degradation of drug in acidic and basic medium was carried in 1N 
HCl and 1N NaOH respectively at 70 °C for a period of 6 h. The 
stressed samples were first cooled to room temperature, followed 
by neutralization and finally the volume was made up to mark by 
mobile phase. Degradation of drug in neutral medium was done by 
treating the drug with water for a period of 6 h at 70 °C.  
Oxidative degradation of the drug was carried by subjecting the drug 
to react with 10% H2O2
RESULTS AND DISCUSSION 
 solution for a period of 6 d. Photolysis of the 
drug was carried by exposing the drug to direct sunlight for 4 d, 
whereas for thermal degradation the drug was heated in an oven at 
80 °C for 9 h. The stressed samples obtained in neutral and thermal 
stress conditions were cooled to room temperature and diluted with 
mobile phase. The oxidative and photolytic stressed samples were 
diluted with mobile phase. The samples of forced degradation 
studies were diluted with mobile phase to give a final concentration 
of 10 µg/ml before injecting in the system.  
Chromatographic separation 
The method involved separation of TA from its two impurities and 
other possible degradants under stress conditions. For carrying out 
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efficient separation effect of various pH of the buffer along with the 
various composition of the mobile phase was studied. The mobile 
phase selected was acetonitrile as organic phase and ammonium 
dihydrogen ortho phosphate as buffer (10 mmol). Various trials 
were carried out with pH of buffer ranging from 2.5 to 6.5. Optimum 
separation of the drug from its specified impurities was obtained 
when the pH of the buffer was fixed at 2.5 and the composition of 
acetonitrile and buffer was in the ratio of 80:20%v/v under isocratic 
elution. The following separation was performed on the available 
Sunfire ODS C-18 (250 x 4.6 mm, 5 µm) column maintained at 40 °C. 
The detection was carried out at 205 nm using flow rate of 1 
ml/min. The optimized chromatographic conditions used for the 
developed method are different from the available method [21] as 
shown in table 1. 
  
Table 1: Optimized chromatographic conditions of the proposed RP HPLC method 
Mobile phase Mixture of acetonitrile and 10 mmol ammonium dihydrogen orthophosphate buffer (pH adjusted to 2.5 with 
orthophosphoric acid) in the ratio of 80:20 % v/v. 
Column Sunfire ODS C18 (4.6 x 250 mm,5 μm) column 
Injection Volume  10 µl 
Flow Rate 1 ml/min 
Column oven temperature  40 °C 
Detection wavelength 205 nm 
 
System suitability 
The developed method at the optimized chromatographic conditions 
efficiently resolved TA from its 2 specified impurities as shown by a 
representative chromatogram in fig. 2. The concentration of TA and 
the two impurities used for the system suitability is 50μg/ml and 
5μg/ml respectively. The system suitabilty parameters of all the 
three components are listed in table 2. 
 
Table 2: System suitability parameters of the proposed RP HPLC method 
S. No. Components Rt RRT Area Resolution Peak asymmetry Theoretical plate 
1 Tolfenamic acid (50 µg/ml) 6.650 - 3218433  NA 1.098 14400 
2 2-Chlorobenzoic acid 3.017 0.453 533577  7.504 1.213 7515 
3 3-chloro-2-methylaniline 4.108 0.617 829977  13.621 1.069 11607 
 
 
Fig. 2: Optimized chromatogram showing separation of tolfenamic acid (TA) from the impurities and also from each other 
 
The obtained chromatogram showed tailing factor of less than 1.3 
for all the peaks, a resolution of more than 2 for CBA and DMA with 
respect to TA. The number of theoretical plates, tailing factor and the 
resolution for the three components were within the limits of 
acceptance criteria (reference) specified in ICH guidelines.  
Specificity 
The chromatogram shown in fig. 2 represented the specificity of the 
developed method in efficiently separating the drug from its two 
impurities as seen from the RRT values and also thus satisfying the 
system suitability parameters. The method was further evaluated to 
check its specificity for the samples obtained after subjecting to 
various stress conditions as compared to the available method 
which is not a stability-indicating method [21]. The results of the 
forced degradation studies are reported in table 3.  
Acidic stress conditions  
The drug after subjecting to react with 1N HCl at 70 °C for 6 h 
showed no significant decrease in the peak area of the drug 
indicating its stability in acidic condition as shown in fig. 3. The 
peaks seen at Rt from 2 to 3 are due to blank samples treated with 
HCl at the detection wavelength. 
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Fig. 2: Representative chromatogram of tolfenamic acid in acidic stress condition 
 
Basic stress condition 
Under the influence of 1N NaOH at 70 °C for 6 h the drug didn’t show 
any degradation, further highlighting its stability in the basic 
medium as shown by fig. 3. The peaks seen at Rt
When the drug was made to react with of water for 6 h at 70 °C it 
showed no degradation as shown by fig. 4. Hence the drug was 
found to be stable in neutral medium. 
 from 2 to 3 are due 
to blank samples treated with NaOH at the detection wavelength. 
Neutral stress condition 
Thermal stress condition 
No degradation of the drug was seen when the drug was kept in 
oven at a temperature of 80 °C for 96 h as confirmed by fig. 5. Thus 
indicating its stability in thermal stress condition. 
Photolytic stress condition 
After exposure of the drug to direct sunlight for 4 d the samples 
showed no degradation of the drug, confirming its stability in the 
applied condition as per fig. 6. 
 
 
Fig. 3: Representative chromatogram of tolfenamic acid in basic stress condition 
 
 
Fig. 4: Representative chromatogram of tolfenamic acid in neutral stress condition 
Fernandes et al. 
Int J App Pharm, Vol 11, Issue 5, 2019, 264-270 
268 
 
Fig. 5: Representative chromatogram of tolfenamic acid in thermal stress condition 
 
 
Fig. 6: Representative chromatogram of tolfenamic acid in photolytic stress condition 
 
Oxidative stress condition 
TA was found to be degraded in oxidative conditions, when treated 
with 10% H2O2 after 2 d. The obtained chromatogram on the sample 
(fig. 7) showed one peak of degradation product along with the peak 
of the drug. The RRT of the degradant formed is 0.54 which is 
different as compared to the RRT value of the two impurities with 
respect to the drug. Hence the formed degradant can be easily 
separated along with the two impurities highlighting the methods 
specificity. The peak at Rt of 2.51 is due to the blank treated sample 




Fig. 7: Representative chromatogram of tolfenamic acid in oxidative stress condition 
Fernandes et al. 
Int J App Pharm, Vol 11, Issue 5, 2019, 264-270 
269 
Table 3: Forced degradation studies of tolfenamic acid (n=2) 
Stress condition Drug recovered (%) Drug decomposed (%) RRT of the degradant  
Standard drug 100 -  
Acidic hydrolysis 90.50 9.5  
Alkaline hydrolysis 90.50 9.5  
Neutral hydrolysis 98.47 1.53  
Oxidative degradation 85.61 14.39 0.54 
Thermal degradation 92.93 7.07  
Photolytic degradation 95.34 4.66  
n=number of determinations for each condition 
 
Linearity 
Standard calibration curves were obtained for TA and its two 
impurities i.e. CBA and CMA. The data showed linearity in the 
range of 10-100µg/ml for TA and 0.1-1µg/ml for CBA and CMA, 
with correlation coefficients of ≥ 0.995 in all the cases which are 
within acceptable range i.e. more than 0.98. Table 4 highlights the 
linearity parameters of the calibration curves for TA and its two 
impurities. 
Precision and sensitivity  
Intraday and intraday precision results obtained for the method are 
listed in the table 4. Percentage RSD values obtained for TA and the 
impurities were less than 2, which were within the acceptance 
criteria. Method sensitivity in terms of LOD and LOQ for TA and the 
impurities are as shown in table 4. 
Accuracy  
Satisfactory percentage recoveries of TA and the impurities were 
obtained at 80,100% and 120% of the test concentration. The 
accuracy results of the method were within the acceptable range of 
95 % to 105% as shown in table 5. 
Robustness  
With deliberate changes in flow rate and in the proportion of organic 
phase in mobile phase, no significant changes in the system suitability 
parameters of the method for TA and for the impurities were seen as 
shown in table 6. Thus the method was found to be robust. 
 
Table 4: Regression parameters of the developed method 
Parameters Tolfenamic acid Impurity A Impurity B 
Range(µg/ml) 10-100 0.1-1 0.1-1 
Regression equation Y=48849x+53707 Y=86129x+2217.4 Y=119746+49.33 
Correlation coefficient 0.9987 09984 0.9989 
Intraday precision(n=3)    
Area (%RSD) 0.81 0.44 0.56 
Interday precision(n=3)    
Area(%RSD) 0.86 0.22 0.82 
LOD(µg/ml) 4.54 0.035 0.042 
LOQ(µg/ml) 13.77 0.106 0.128 
n= number of determinations 
 
Table 5: Accuracy data of drug and its impurities (n=3) 

















Tolfenamic acid  80 32 30.70 95.96±0.88 0.91 
40 100 40 40.20 99.99±1.6 1.60 
 120 48 47.09 98.11±0.78 0.79 
2-chloro benzoic acid (Impurity A)  80 0.32 0.31 96.82±1.34 1.38 
0.4 100 0.4 0.41 103.1±0.65 0.63 
 120 0.48 0.47 99.79±0.22 0.22 
3-Chloro 2-methylaniline (Impurity B)  
 
 80 0.32 0.3204 100.12±0.70 0.70 
0.4 100 0.4 0.399 99.90±0.72 0.72 
 120 0.48 0.47 97.14±1.76 1.81 
n = number of determinations, SD= Standard Deviation, %RSD=% Relative Standard Deviation 
 
Table 6: Results of robustness studies (n=3) 
Variable Tolfenamic acid area (%RSD) Impurity A area (%RSD) Impurity B area (%RSD) 
Change in flow rate    
0.8 ml/min 0.35 0.39 1.77 
1.2 ml/min 0.77 1.21 0.71 
Change in composition of mobile phase 
(ACN: Buffer) 
   
78:22v/v 0.81 1.86 0.52 
82:18 v/v 0.35 0.71 0.13 
n= number of determinations, (%RSD) =% Relative Standard deviation 
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CONCLUSION 
A RP HPLC method was developed and validated as per ICH 
guidelines for estimation of TA in the presence of its two 
Pharmacopoeial impurities as well as degradation products. The 
method was found to be stability-indicating from the results 
obtained after application of the method to the stress samples of TA. 
The drug TA showed stability in acidic, basic, neutral, photo and 
thermal stress conditions and indicated degradation in oxidative 
stress conditions. The developed stability-indicating method is 
found to be simple, rapid, accurate, precise and robust as compared 
to other proposed methods while determining TA in presence of 
specified impurities and degradation products. Hence, the proposed 
method can be used for routine and stability sample analysis of TA.  
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